Progenies Receives FDA approval of first-and-only Azerda (iobenguane I 131) to treat Unresectable, LA/M Pheochromocytoma/Paraganglioma

 Progenies Receives FDA approval of first-and-only Azerda (iobenguane I 131) to treat Unresectable, LA/M Pheochromocytoma/Paraganglioma

Progenies Receives FDA approval of first-and-only Azerda (iobenguane I 131) to treat Unresectable, LA/M Pheochromocytoma/Paraganglioma

Shots:
  •  AZEDRA radio therapeutic indicated to treat adult and pediatric patients 12yrs with iobenguane scan positive 
  •  Has shown reduction rate in need of blood pressure medication and tumor size in patients for approved IV dose 555MBq/mL
  •  Approval was based on pivotal Ph 2 under SPA showing 17/68 (25%) 50% patients showed reduction in medication and tumor response of almost 53%

Click here to read full press release/ article | Ref: Progenics Pharmaceuticals | Image:  LinkedIn

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post